ZZUNEUi027-A
General
Cell Line |
|
hPSCreg name | ZZUNEUi027-A |
Cite as: | ZZUNEUi027-A (RRID:CVCL_B7T2) |
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
FAMRCi006-A (LMNA T3) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy FAMRCi006-B (LMNA T4) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy ZJSHi001-A (ZJSHi-KCNB1) Donor's gene variants: KCNB1 Donor diseases: developmental and epileptic encephalopathy, 26 SCVIi073-A (SCVIi574C2) Donor's gene variants: titin, BAG cochaperone 3, BAG cochaperone 3 Donor diseases: Dilated Cardiomyopathy SCVIi074-A (SCVIi599C1) Donor's gene variants: BAG cochaperone 3 Donor diseases: Hypertrophic Cardiomyopathy |
Last update | 9th June 2022 |
User feedback | |
Provider |
|
Generator |
ZhengZhou University- The first affiliated hospital(ZZU) (ZZUNEU)
Contact:
The first affiliated hospital (ZZU) |
Owner | The first affiliated hospital (ZZU) |
Derivation country | China |
External Databases |
|
BioSamples | SAMEA14328246 |
Cellosaurus | CVCL_B7T2 |
Wikidata | Q112930601 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 15-19 |
Ethnicity | Han nationality |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Is the medical history available upon request? | yes |
Is clinical information available? | yes |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
BioSamples | SAMEA14328247 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | 393568874@qq.com |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Ethics Committee of the First Affiliated Hospital of Zhengzhou University |
Approval number | 2018-KY-38 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Age of donor (at collection) | 15-19 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Is reprogramming vector detectable? |
No |
Methods used |
RT-PCR
|
Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Yes |
Derived under GMP? |
No |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SSEA-4 |
Yes |
|
|
|||
NANOG |
Yes |
|
Marker | Present | Absent |
mCpG | ||
OCT4 |
Differentiation Potency
In vitro directed differentiation
Morphology
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.